Cantor Fitzgerald released a research report on July 25, 2026, trimming the target price for Celldex Therapeutics.
6 reports, 1 independent
Updated Sep 26
Gone quiet
- Reports
- 6
- Developments
- 1
- Repetition
- 83%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald released a research report on July 25, 2026, trimming the target price for Celldex Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
- The event reports that Brooke Rollins serves as Trump's Agriculture Secretary and notes that Lutnick previously ran Cantor Fitzgerald.
- Agilysys CEO Ramesh Srinivasan sold significant company shares, with the transaction disclosed via filings with the SEC, concurrent with a rating from Cantor Fitzgerald.
-
Celldex Therapeutics
American biopharmaceutical company
Nothing else this week.
Related events
- Analyst provides a high price target for Viking Therapeutics stock.
- Bristol-Myers Squibb's price target was cut by Cantor Fitzgerald following clinical setbacks.
- Cantor Fitzgerald and Benchmark issued rating and price target updates for First Financial Bankshares Inc.
- Cantor Fitzgerald raised price targets and reaffirmed ratings, while TD Cowen adjusted its ratings for Paylocity on August 7, 2026.
- Leerink Partners, Truist Financial, HSBC, and Cantor Fitzgerald raised target prices on various stocks on October 9, 2026.
Coverage
Newest first; wire copies grouped- tickerreport.comCantor Fitzgerald Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $61.00